Sahyun, M. R. V., Nature, 203, 1045 (1964).

Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company harnessing the power of human genetics to ...

The A/G ratio is a blood test that measures levels of albumin and globulin, the two main proteins in your blood. A high albumin to globulin (A/G) ratio may indicate kidney disease, an antibody ...

Feb. 7, 2025 — A complex molecular machine, the spliceosome, ensures that the genetic information from the genome, after being transcribed into mRNA precursors, is correctly assembled into ...

Cells navigating in complex microenvironments frequently encounter narrow spaces that physically challenge migration.

Maze Therapeutics, Inc. (NASDAQ: MAZE), a clinical-stage biopharmaceutical company with a market capitalization of $569 million, has dosed the first patient in its Phase 2 HORIZON Study of MZE829, ...

According to Future Market Insights’ updated report, the renal biomarker market is projected to experience steady growth over ...

Molecular dynamics is a method that uses Newton’s equations of motion to computationally simulate the time evolution of a set of interacting atoms. Such techniques are dependent on a description ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a ...

Delta4 receives European patents for two compounds as candidate treatments for focal segmental glomerulosclerosis: Vienna, Austria Monday, February 3, 2025, 18:00 Hrs [IST] Delta4 ...

Correspondence to: Prof. M Levin, Department of Paediatrics, Faculty of Medicine, Imperial College of Science, Technology & Medicine, Norfolk Place, London W2 1PG, UK; m.levin{at}ic.ac.uk Neisseria ...